Eikon Therapeutics, Inc. Common Stock (EIKN) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.21x
Eikon Therapeutics, Inc. Common Stock (EIKN) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of $-64.96 Million could theoretically repay 0% of its total liabilities ($313.07 Million) in one year. See EIKN free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.21x
Operating CF / Total Liabilities
Operating Cash Flow
$-64.96 Million
USD
Total Liabilities
$313.07 Million
USD
Data as of
Jun 2026
Most recent filing
Eikon Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for Eikon Therapeutics, Inc. Common Stock across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Eikon Therapeutics, Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for Eikon Therapeutics, Inc. Common Stock (2023–2025)
Year-by-year debt coverage analysis for Eikon Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | $-188.52 Million | $1.47 Billion | ▼ -0.9% |
| 2024 | -0.13x | $-134.80 Million | $1.06 Billion | ▲ +42.4% |
| 2023 | -0.22x | $-190.85 Million | $867.08 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.